StockNews.AI
GSK
StockNews.AI
2 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc – GSK

1. Pomerantz LLP investigates potential securities fraud involving GSK and its leadership. 2. The FDA's ODAC rejected GSK's dosage proposal for Blenrep, affecting stock price. 3. GSK's stock fell 4.73% following negative FDA advisory committee news. 4. Investors are encouraged to contact Pomerantz for potential class action participation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

Negative FDA recommendations typically lead to immediate stock sell-offs; historical similar events show significant market reactions, as seen with companies like Amgen and their failed drug applications.

How important is it?

The combination of potential legal investigations and a negative FDA ruling creates a high likelihood of impacting GSK's stock negatively.

Why Short Term?

The immediate fallout from FDA advisory decisions often results in short-lived but pronounced market reactions, such as the decline observed post-announcement.

Related Companies

AMGNNVSPFE
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether GSK and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On July 17, 2025, GSK issued a press release announcing “that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.”  On this news, GSK’s American Depositary Receipt (“ADR”) price fell $1.81 per share, or 4.73%, to close at $36.47 per share on July 17, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News